# LEE, HERNANDEZ, LANDRUM

### IN THE SUPREME COURT OF THE STATE OF NEVADA

MICHAEL KIRSCH; AND SIU YIP,

Appellants,

v.

6

1

2

3

4

5

7

8 9

10

11

12

13 14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Supreme Court No. 70854

District Court Electronically Filed 7-Mar 14 2017 04:05 p.m. Elizabeth A. Brown

Clerk of Supreme Court

CZIRR; JACK W. CALLICUTT; GILBERT F. AMELIO; KEVIN D. FREEMAN; ARTHUR R. GREENBERG; ROD D. MARTIN;

JOHN F. MAULDIN; STEVEN

PETER G. TRABER; JAMES C.

PRELACK; HERMAN PAUL

PRESSLER, III; DR. MARC RUBIN;

AND GALECTIN THERAPEUTICS, INC., A NEVADA CORPORATION,

Respondents.

### APPENDIX TO APPELLANT'S OPENING BRIEF **VOLUME III**

Submitted by:

DAVID S. LEE, ESQ.

Nevada Bar No. 6088

NATASHA A. LANDRUM, ESQ.

Nevada Bar No. 7414

DIRK W. GASPAR, ESQ.

Nevada Bar No. 10046

LEE, HERNANDEZ, LANDRUM & GAROFALO, A.P.C.

7575 Vegas Drive, Suite 150

Las Vegas, NV 89128

Phone: (702) 880-9750 Fax: (702) 314-1210

1

## LEE, HERNANDEZ, LANDRUM & GAROFALO 7575 VEGAS DRIVE, SUITE 150 LAS VEGAS, NV 89128 (702) 880-9750

### APPELLANT'S APPENDIX

DOCUMENT DESCRIPTION	FILING DATE	BATES NUMBER	VOLUME NUMBER
Order re: Motion to Dismiss	4/1/2016	APP000001 -	I
Shareholder Derivative Action	4/1/2010	APP000004	1
Notice of Entry of Order	6/16/2016	APP000005 -	I
Denying Motion to Correct	0/10/2010	APP000010	1
Order re: Motion to Dismiss			
Shareholder Derivative Action			
Notice of Appeal	7/15/2016	APP000011 -	I
11		APP000019	
Verified Shareholder Derivative	8/29/2014	APP000020 -	I
Complaint		APP000045	
Defendants' Motion to Stay the	11/17/2014	APP000046 -	I
Case in Deference to Prior-Filed		APP000165	
Parallel Derivative Litigation			
and Supporting Memorandum			
of Law			
Court Minutes	12/19/2014	APP000166	I
Defendants' Motion for	1/8/2015	APP000167 -	I
Reconsideration of Ruling		APP000189	
Denying Defendants' Motion to			
Stay Case and Supporting			
Memorandum of Points and			
Authorities			
Memorandum in Support of	3/19/2015	APP000190 -	II
Plaintiff's Motion for Leave to		APP000285	
file Plaintiff's Second Amended			
Shareholder Derivative			
Complaint	2/27/2015	4 DD000000	TT
Plaintiff's Second Amended	3/27/2015	APP000286 -	II
Shareholder Derivative		APP000368	
Complaint Individual Defendants' Motion	4/22/2015	APP000369 -	III
to Dismiss the Second	4/22/2013	APP000559	111
Amended Shareholder		ATT 000339	
Derivative Complaint and			
Memorandum of Points and			
Authorities			
		L	

DOCUMENT DESCRIPTION	FILING DATE	BATES NUMBER	VOLUME NUMBER
Nominal Defendant Galectin	4/22/2015	APP000560 -	IV
Therapeutics, Inc.'s Motion to	4/22/2013	APP000759	l v
Dismiss the Second Amended		1111000737	
Shareholder Derivative			
Complaint and Memorandum of			
Points and Authorities			
Plaintiff's Combined	5/20/2015	APP000760 -	IV
Memorandum of Law in	3/20/2013	APP000798	1
Opposition to the Nominal		111 000750	
Defendant and Individual			
Defendants' Motions to Dismiss			
the Second Amended			
Shareholder Derivative			
Complaint			
David L. Hasbrouck and Siu	5/29/2015	APP000799 -	V
Yip's Motion to Intervene	0,2,,2010	APP000992	,
Individual Defendants' Reply	6/4/2015	APP000993 -	V
Memorandum in Support of	0, 1, 2020	APP000999	
their Motion to Dismiss the			
Second Amended Shareholder			
Derivative Complaint			
Nominal Defendant Galectin	6/4/2015	APP001000 -	V
Therapeutic, Inc.'s Reply		APP001043	
Memorandum in Support of its			
Motion to Dismiss the Second			
Amended Shareholder			
Derivative Complaint			
Notice of Entry of Order Re:	8/10/2015	APP001044 -	VI
June 11, 2015 Motions to		APP001049	
Dismiss and Motion to Join			
Additional Plaintiffs			
Individual Defendants' and 10X	1/19/2016	APP001050 -	VI
Fund, L.P.'s Motion to Dismiss		APP001054	
Shareholder Derivative Action			
Nominal Defendant Galectin	1/19/2016	APP001055 -	VI
Therapeutic, Inc.'s Motion to		APP001470	VII
Dismiss Shareholder Derivative			
Action			

DOCUMENT	FILING	BATES	VOLUME
DESCRIPTION	DATE	NUMBER	NUMBER
Court Minutes	3/3/2016	APP001471 -	VII
		APP001472	
Transcript of Proceedings on	11/3/2015	APP001473 -	VIII
November 3, 2015		APP001549	
Corrected Transcript of	3/16/2016	APP001550 -	VIII
Proceedings on March 3, 2016		APP001560	

DATED this 14th day of March, 2017.

LEE, HERNANDEZ, LANDRUM & GAROFALO, A.P.C.

By:

DAVID S. LEE, ESQ.
Nevada Bar No. 6088
NATASHA A. LANDRUM, ESQ.
Nevada Bar No. 7414
DIRK W. GASPAR, ESQ.
Nevada Bar No. 10046
7575 Vegas Drive, Suite 150
Las Vegas, NV 89128

EDWARD W. MILLER, ESQ. (admitted *pro hac vice*)
JOSHUA M. LIFSHITZ, ESQ.
LIFSHITZ AND MILLER
821 Franklin Avenue, Suite 209
Garden City, New York
Attorneys for Appellant

### FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol							g Syml	bol 5. Relati (Check a	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
10X Fund, L.	P.				GALECTIN THERAPEUTICS INC [ GALT ]						CS IN	VCDire	ctor	_	_X 10% (	Owner	
(Last)	(First)	(	(Middle)		3. Date of Earliest Transaction (MM/DD/YYYY)						D/YYYY	Y)Offi	cer (give title	below) _	Other	specify	
1099 FOREST LAKE TERRACE							1.	/1	0/201	4							
	(Street)					Amendm DD/YYYY)		at	e Orig	inal	Filed		6. Indivi Applicable	dual or Joi Line)	nt/Group 1	Filing (Che	eck
NICEVILLE (City)	, FL 325 (State)		(Zip)										Form f	iled by One R a filed by Mor	eporting Pers than One Re	on eporting Pers	on
		Tab	le I - Nor	ı-Deri	ivati	ve Secur	ities A	λc	quired	l, Di	spose	ed of,	or Beneficia				
1.Title of Security (Instr. 3)				2. Tr Date	e Deemed		3. Trans Code (Instr. 8	or Disp	Disposed of (D) Own						Ownership Form:	7. Nature of Indirect Beneficial Ownership	
						any	Code	v	Amoun	(A) or t (D)	Pı	rice	(LISH. 3 and 4)			or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock				1/10/	/2014		S		42000 (1)	D	\$16.00	028 (2)	ç	9415422 <sup>(3)</sup>		D	
Common Stock				1/13/	/2014		S		58000 (1)	D	\$14.00	035 (4)	Ş	9357422 <sup>(3)</sup>		D	
Tal	ble II - De	rivati	ive Securi	ities B	Benef	ficially O	wned	(	e.g. , p	outs,	calls	, war	rants, optior	ıs, convert	ible secur	ities)	
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A. Deemed Execution	4. Frans. Code	5. N Deri Secu Acq Disp	fumber of ivative urities uired (A) or posed of (D) tr. 3, 4 and	6. Dar and E	te E	exercisat ration D	ole ate	7. Tit Secun Deriv (Instr	ele and A rities Ur vative So : 3 and	Amount of iderlying ecurity 4)		9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	/ (A	) (D)	Date Exerc	isal	Exp.	iration	Title	Amour Shares	at or Number of				

#### **Explanation of Responses:**

- (1) The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the Issuer's Executive Chairman that occurred on November 15, 2013. The issuer is taking steps to collect any short-swing profit created by such transactions.
- (2) Reflects weighted average price. Range of prices were between \$15.68 and \$16.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (3) 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- (4) Reflects weighted average price. Range of prices were between \$13.65 and \$14.23. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Panartina Owner Name / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
10X Fund, L.P. 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578		X						
10X Capital Management, LLC 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578		X						

#### Signatures

/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	1/14/2014
** Signature of Reporting Person	Date
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	1/14/2014
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT K

## EXHIBIT K

APP000519

## GALECTIN THERAPEUTICS INC Reported by 10X CAPITAL MANAGEMENT, LLC

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 10/09/13 for the Period Ending 10/07/13

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31



[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol							ibol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
10X Fund, L.P	•				GALECTIN THERAPEUTICS INC [GALT]							Directo	or	_	X10% (	Owner	
(Last)	(First)	(	Middle)	3.	3. Date of Earliest Transaction (MM/DD/YYYY)						Y)	Officer (give title below) Other (specify below)			specify		
1099 FOREST	LAKE	TE	RRACI	E			1	0/	7/201:	3							
	(Street)					mendm D/YYYY)	ent, D	at	e Origi	nal	Filed		6. Individual or Joint/Group Filing (Check Applicable Line)				
NICEVILLE, I	FL 325	78		:													
(City)	(State)	(	(Zip)												eporting Person than One Re		on
		Tab	le I - Non			e Securi	ties A	\c(	quired.	, Di	sposed of,	or E	Beneficially	Owned			
			2. Trai Date	þ	3. Trans Code Instr. 8	or Disposed of (D) (Instr. 3, 4 and 5)				Owi	Amount of Securities Beneficially whed Following Reported Transaction(s) astr. 3 and 4)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership			
						any	Code	v		(A) or (D)	Price					or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock				10/7/2	2013		S		100000	D	\$11.7916 <sup>(1</sup>	)	89	069422		Œ	
Common Stock				10/8/2	2013		s		12000	D	\$12.3558 <sup>(2</sup>	()	895	7422 (3)		D	
Table	e II - De	rivati	ve Securi	ities Be	enefi	cially O	wned	(	<i>e.g.</i> , p	uts,	calls, was	ran	ts, options,	convert	ible secur	ities)	
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Deemed Execution Oate, if any	Frans. Code (Instr. 8)	Deriv Secun Acqu Dispo	rities ired (A) or osed of (D)	and E	xpi	Expirate Date	te	7. Title and Securities Uperivative S (Instr. 3 and Title Amou	Inderly Securit (14)	ying	8. Price of Derivative Security (Instr. 5)	of derivative Securities Beneficially Owned Following Reported	Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)

#### **Explanation of Responses:**

- (1) Reflects weighted average price. Range of prices were between \$11.5335 and \$12.136. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (2) Reflects weighted average price. Range of prices were between \$12.00 and \$12.51. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (3) 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

**Reporting Owners** 

Reporting Owner Name / Address	Relationships									
Reporting Owner Name / Address	Director	10% Owner	Officer	Other						
10X Fund, L.P. 1099 FOREST LAKE TERRACE		X								

1		1 1
NICEVILLE, FL 32578		
10X Capital Management, LLC 1099 FOREST LAKE TERRACE	X	
NICEVILLE, FL 32578		

#### Signatures

/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	10/9/2013
** Signature of Reporting Person	Date
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	10/9/2013
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT L

## EXHIBIT L

APP000523

## GALECTIN THERAPEUTICS INC

## Reported by CZIRR JAMES C

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 10/09/13 for the Period Ending 10/07/13

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

### FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
CZIRR JAM	ES C			[6	GALT]					TICS IN	_x_	Director	10% (	Owner	
(Last)	(First)	(	Middle)	3. I	3. Date of Earliest Transaction (MM/DD/YYYY)						below)	Officer (give title below)	Othe	r (specify	
C/O GALEC	TIN TH	ERA	PUETI	CS,		10	0/	7/2013	3		Bacca	die Chan man			
INC., 7 WEL	LS AVE	NUI	E, SUIT	E											
34											No.				
	(Street)				f Amendn M/DD/YYYY		at	te Origi	nal	Filed		ividual or Joint/Group I ble Line)	Filing (Che	ck	
NEWTON, M. (City)	IA 02459 (State)		(Zip)									orm filed by One Reporting Per on filed by More than One Repo		n	
		Tab	le I - Nor	ı-Deriva	tive Secu	rities A	\c	quired	, Di	sposed of,		ially Owned	<u> </u>		
		2. Trans Date	Deemed Execution	3. Trans. Code (Instr. 8)		or Disposed of (D) Own (Instr. 3, 4 and 5)			Owned Follo	<ul> <li>Amount of Securities Beneficially Owned Following Reported Transaction(s)</li> <li>Instr. 3 and 4)</li> </ul>		7. Nature of Indirect Beneficial			
					Date, if any	Code	v	Amount	(A) or (D)	Ргісе	(msu. 3 and	4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock						ŀ						843450	D		
Common Stock				10/7/201	13	s		100000	D	\$11.7916 <sup>(1)</sup>		8969422	I	By 10X Fund, L.P.	
Common Stock				10/8/201	13	s		12000	D	\$12.3558 <sup>(2)</sup>		8957422 <sup>(3)</sup>	I	By 10X Fund, L.P. <sup>(3)</sup>	
Common Stock				+	-		$\vdash$					179232	I	By Trust	
Tal	ble II - De	rivati	ive Secur	ities Ben	eficially (	Owned	l (	<i>e.g.</i> , p	uts,	calls, war	rants, opti	ions, convertible secur	ities)	1	
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A. Deemed Execution	4. 5. Trans. Code (Instr. 8) A D (I	Number of Derivative ecurities cquired (A) or Disposed of (Dinstr. 3, 4 and	6. Da and F	te l	Expi	le ate	7. Title and A Securities Ur Derivative So (Instr. 3 and	Amount of inderlying ecurity 4)	8. Price of Derivative of Security (Instr. 5) Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

#### **Explanation of Responses:**

- (1) Reflects weighted average price. Range of prices were between \$11.5335 and \$12.136. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (2) Reflects weighted average price. Range of prices were between \$12.00 and \$12.51. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities of the r

the extent of his pecuniary interest therein.

Reporting Owners

Donorting Owner Name / Address		Re	lationships	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CZIRR JAMES C C/O GALECTIN THERAPUETICS, INC.				
7 WELLS AVENUE, SUITE 34 NEWTON, MA 02459	X		Executive Chairman	

#### **Signatures**

/s/ James C. Czirr 10/9/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT M

## EXHIBIT M

APP000527

## GALECTIN THERAPEUTICS INC

## Reported by MARTIN ROD D

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 10/09/13 for the Period Ending 10/07/13

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

### Fowered By EDGAROnline



[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	ress of Re	portir	ng Person	*	2. Is	suer Nam	ne and	l Ti	icker or	Tra	ading	Symt	ool 5. Relation (Check al	nship of F I applicab		Person(s)	to Issuer
Martin Rod D	)				GA	LECTI	(T A	H	ERAP	EU	TIC	S IN	IC				
					[ G.	ALT]							X_Dire	ector		10% (	Owner
(Last)	(First)	(	Middle)		3. D	ate of Ea	rliest 7	Гга	insactio	n (M	/M/DD	)/YYYY	() Office below)	er (give title b	elow) _	Other (	specify
C/O GALEC	TIN TH	ERA	PEUT	CS,			1	0/	7/2013	3							
INC., 4960 PI				•													
INDUSTRIA	L BLVI	, ST	E 240														
	(Street)					Amendn DD/YYYY		Dat	e Origi	nal	Filed		6. Individ Applicable I	lual or Join Line)	nt/Group 1	Filing (Che	eck
NEWTON, M	IA 0245	9															
(City)	(State)	(	(Zip)											filed by One l led by More t			n
		Tab	le I - Noi	n-Der	ivati	ive Secui	cities A	Acc	quired,	Dis	spose	d of, o	or Beneficial	ly Owned			
1. Title of Security (Instr. 3)				2. T Date	rans.	2A. Deemed Execution Date, if	3. Tran Code (Instr. 8		4. Securi or Dispo (Instr. 3,	sed c	of (D)	ed (A)	5. Amount of Sec Owned Followin (Instr. 3 and 4)			6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
						any	Code	v	Amount	(A) or (D)	Pr	ice	(msu. 5 and 4)			or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock														91488		D	
Common Stock				10/7	7/2013		s		100000	D	\$11.79	916 <sup>(1)</sup>		8969422		I	By 10X Fund, L.P.
Common Stock				10/8	3/2013		s		12000	D	\$12.35	558 <sup>(2)</sup>	89	957422 <sup>(3)</sup>		1	By 10X Fund, L.P.
Tab	ole II - De	rivati	ve Secur	ities 1	Bene	ficially (	Owned	1 (	<i>e.g.</i> , p	uts,	calls	, warı	rants, option	s, convert	ible secur	rities)	
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A. Deemed Execution	4. Trans. Code (Instr. 8	5. 1 Der Sec 3) Acc Dis	Number of rivative curities quired (A) o sposed of (D str. 3, 4 and	6. Da and F	ite E Expi	Exercisabl iration Da	e te	7. Tit Secur Deriv (Instr	le and A rities Un rative Se 3 and 4	Amount of Iderlying Ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Number	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V (A	A) (D)	Date Exerc		Expir ble Date	ation	Title	Amoun Shares	at or Number of		(s) (Instr. 4)	] <sup>")</sup>	

#### **Explanation of Responses:**

- (1) Reflects weighted average price. Range of prices were between \$11.5335 and \$12.136. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (2) Reflects weighted average price. Range of prices were between \$12.00 and \$12.51. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (3) Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Reporting Owners

Reporting Owner Name / Address	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Martin Rod D									
C/O GALECTIN THERAPEUTICS, INC.									
4960 PEACHTREE INDUSTRIAL BLVD, STE 240	$\mathbf{X}$								
NEWTON, MA 02459									

#### Signatures

/s/ Rod D. Martin

10/9/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBITN

## EXHIBIT N

APP000531

### GALECTIN THERAPEUTICS INC

## Reported by CZIRR JAMES C

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 01/14/14 for the Period Ending 01/10/14

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	iress of Re	eporting Perso	n*	2. Is:	suer Nan	ne and	Τ	icker o	r Tr	ading Sy	mbo	ol 5. Relationship of F (Check all applicab	Reporting le)	Person(s)	to Issuer
CZIRR JAM	ES C				LECTI ALT ]	(N T)	1	ERAP	EU	JTICS	IN	C X_Director		10%	Owner
(Last)	(First)	(Middle)		3. D	ate of Ea	rliest '	Γra	nsactio	n (N	MM/DD/YY	(YY)	X_Officer (give title	below)	Othe	τ (specify
C/O GALEC INC., 4960 PI INDUSTRIA	EACHT	REE	,			1	/1	0/2014	4		)	Executive Chairm	an		
	(Street)				Amendn DD/YYYY		)at	e Origi	nal	Filed		6. Individual or Join Applicable Line)	nt/Group )	Filing (Ch	eck
NORCROSS,	GA 300	071													
(City)	(State)	(Zip)		£								X Form filed by One I Form filed by More f			n
1.Title of Security (Instr. 3)		Table I - No	2. T	rans.	2A.	3. Tran	~~~	4. Secur	ities .	Acquired (A	A) 5	r Beneficially Owned 5. Amount of Securities Benef	icially	6.	7. Nature
(msu. 5)			Date	9	Deemed Execution Date, if	Code (Instr. 8	3)	or Dispo (Instr. 3,				Owned Following Reported Tr	ransaction(s)	Form:	Beneficial
					any	Code	v	Amount	(A) or (D)	Price	(	Instr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock												844450		D	
Common Stock			1/10	/2014		s		<b>42000</b> (1)	D	\$16.0028	(2)	9415422 <sup>(3)</sup>		I	By 10X Fund, L.P.
Common Stock			1/13	3/2014		S		58000 (1)	D	\$14.0035	(4)	9357422 (3)		I	By 10X Fund, L.P.
Common Stock			Щ				_		L	L		179232		I	By Trust
Tab	ole II - De	rivative Secu	rities I	Benei	ficially C	)wned	(	<i>e.g.</i> , pi	uts.	calls, wa	arra	ants, options, converti	ble secur	rities)	
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. 3A.	4. Trans. Code (Instr. 8	5. N Deri Secti Acq Disp (Ins:	fumber of ivative urities uired (A) or oosed of (D) tr. 3, 4 and	6. Dar and E	e E	Expir	e te	7. Title an Securities Derivative (Instr. 3 and	d An Unde Second 4)	nount of 8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Ĺ	<u></u>		Code V	V (A	) (D)	Ехего	isal	ble Date		Shar	res		(s) (Instr. 4)		

#### **Explanation of Responses:**

- (1) The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the Issuer's Executive Chairman that occurred on November 15, 2013. The issuer is taking steps to collect any short-swing profit created by such transactions.
- (2) Reflects weighted average price. Range of prices were between \$15.68 and \$16.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (3) Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.

APP000533

(4) Reflects weighted average price. Range of prices were between \$13.65 and \$14.23. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
CZIRR JAMES C C/O GALECTIN THERAPUETICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD. STE. 240	X		Executive Chairman	l				
NORCROSS, GA 30071								

#### Signatures

/s/ James C. Czirr

1/14/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

<sup>\*\*</sup> Signature of Reporting Person

## EXHIBIT O

## EXHIBIT O

APP000535

## GALECTIN THERAPEUTICS INC

## Reported by MARTIN ROD D

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 01/14/14 for the Period Ending 01/10/14

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

### FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				* 2	2. Issuer Name and Ticker or Trading Symbol									nship of F applicab		ng Person(s) to Issuer			
Martin Rod I	)					LECTI ALT]	NTI	H	ERAP	EU	TICS IN	1C	_X _ Dire	ctor		10%	Owner		
(Last)	(First)	(	Middle)	3	3. Da	ite of Eai	rliest 7	Γra	nsactio	n (N	1M/DD/YYYY	Y) b	Office elow)	r (give title l	pelow)	Other	(specify		
C/O GALEC' INC., 4960 PI	EACHT	REE	1	CS,			1.	/1	0/2014	1									
INDUSTRIA	(Street)		E 240			Amendn DD/YYYY)		Dat	e Origi	nal	Filed		5. Individ Applicable L		nt/Group 1	Filing (Che	eck		
NORCROSS. (City)	(State)		(Zip)										X_Form file	iled by One ed by More t	Reporting Pe han One Rep	rson orting Perso	n		
		Tab	le I - Nor	ı-Deri	ivati	ve Secur	ities A	<b>Ac</b>	·		sposed of,			-		<b>40.0</b>			
1.Title of Security (Instr. 3)				2. Tr Date		2A. Deemed Execution Date, if	3. Trans Code (Instr. 8		4. Securi or Dispo (Instr. 3,	sed c 4 an		Owne	nount of Sec ed Following . 3 and 4)	urities Benet Reported T		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
		-				any	Code	v	Amount	(A) or (D)	Price					or Indirect (I) (Instr. 4)	(Instr. 4)		
Common Stock														91488		D			
Common Stock	-			1/10/	/2014		s		42000 (1)	Ð	\$16.0028 <sup>(2)</sup>		94	15422 <sup>(3)</sup>		I	By 10X Fund, L.P.		
Common Stock				1/13/	/2014		s		58000 (1)	D	\$14.0035 <sup>(4)</sup>		93	57422 <sup>(3)</sup>		I	By 10X Fund, L.P.		
Tal	ole II - De	rivati	ive Secur	ities B	Benef	ficially C	)wned	1(	<i>e.g.</i> , p	uts,	calls, war	rants	s, options	, convert	ible secur	rities)			
1. Fitle of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Deemed Execution	4. Frans. Code (Instr. 8)	Deri Secu Acq Disp	fumber of ivative urities uired (A) or cosed of (D) tr. 3, 4 and	and E		Exercisabl ration Da	te	7. Title and A Securities Ur Derivative So (Instr. 3 and A	nderlyin ecurity 4)	ng	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction	Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	/ (A	) (D)	Exerc	isa	ble Date		Title Shares				(s) (Instr. 4)				

#### **Explanation of Responses:**

- (1) The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the Issuer's Executive Chairman that occurred on November 15, 2013. The issuer will take steps to collect any short-swing profit created by such transactions.
- (2) Reflects weighted average price. Range of prices were between \$15.68 and \$16.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- (3) Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- (4) Reflects weighted average price. Range of prices were between \$13.65 and \$14.23. The reporting person will provide upon request by APP000537

the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Reporting Owners

Reporting Owner Name / Address	Relationships								
iceporting Owner Ivalue / Address	Director	10%	Owner	Officer	Other				
Martin Rod D									
C/O GALECTIN THERAPEUTICS, INC.									
4960 PEACHTREE INDUSTRIAL BLVD, STE 240	X								
NORCROSS, GA 30071									

#### Signatures

/s/ Rod D. Martin

1/14/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \*. If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT P

## EXHIBIT P

### GALECTIN THERAPEUTICS INC

## Reported by CZIRR JAMES C

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 11/18/13 for the Period Ending 11/15/13

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

### Powered By EDGAROnline

### FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	lress of Re	porti	ng Person <sup>*</sup>	2	. Issu	er Name	and T	ic	ker or T	rac	ling Sy	mbol	5. Relation (Check all			Person(s)	to Issuer
CZIRR JAM	ES C			1		ECTI	HT P	E)	RAPE	U']	TICS	INC					
					GA	LT]							X_Direc	ctor		10% (	Owner
(Last)	(First)	(	(Middle)	3	. Dat	e of Earl	iest Tr	ans	saction	(MI	A/DD/YY	YYY)	below)	er (give title	,	Othe	r (specify
C/O GALEC				CS,			11/	15	/2013				Executive	Chairm	an		
INC., 4960 PI																	
INDUSTRIA	L BLVI	). ST	E. 240														
	(Street)					mendme	ent, Da	te	Origina	1 F:	iled		6. Individi Applicable Li		nt/Group I	Filing (Che	eck
NORCROSS.	GA 300	071															
(City)	(State)	(	(Zip)										X Form file	led by One : d by More t	Reporting Pe han One Rep	rson orting Person	n
		Tab	le I - Non-	Deriv	vativ	e Securi	ties Ac	qu	uired, E	isp	osed o	f, or F	<b>Beneficially</b>	y Owned			
1. Title of Security (Instr. 3)				2. Tra Date		2A. Deemed Execution Date, if any	3. Trans Code (Instr. 8	)	4. Securit (A) or Di (D) (Instr. 3,	spos I an	ed of	Follow	ount of Securiti ing Reported T 3 and 4)			6. Ownership Form: Direct (D) or Indirect	Beneficial Ownership
							Code	v	Amount	(A) or (D)	Price					(I) (Instr. 4)	(msu. 4)
Common Stock				11/15	5/2013		P		1000	A	\$6.897		84	4450		D	
Common Stock													9457	422 (1)		I	By 10X Fund, L.P.
Common Stock													17:	9232		I	By Trust
Tat	ole II - De	rivati	ive Securit	ies Be	enefi	cially O	wned (	e.,	g., put	ь, с	alls, w	arran	ts, options.	convert	ible secur	rities)	-
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A. 4. Deemed Tr Execution Co	ans.	5. Nur Derive Secur Acqui Dispo	mber of ative	6. Date and Exp	Exe	ercisable tion Date	; ; ;	7. Title an Securities Derivative Instr. 3 and	nd Amou Underly e Securi nd 4)	nt of ying ty	8. Price of Derivative	9. Number	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	Beneficial
			С	ode V	(A)	(D)	Date Exercis	able	Expirati Date	on	Title Sha		Number of		(s) (Instr. 4)	]	

#### **Explanation of Responses:**

(1) Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Reporting Owners				
Reporting Owner Name / Address		Re	lationships	
Reporting Owner Wante / Address	Director	10% Owner	Officer	Other
CZIRR JAMES C C/O GALECTIN THERAPUETICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD. STE. 240	0 X		Executive Chairman	i.
NORCROSS, GA 30071				

Signatures

/s/ James C. Czirr

11/18/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT Q

## EXHIBIT Q APP000543

## GALECTIN THERAPEUTICS INC Reported by 10X CAPITAL MANAGEMENT, LLC

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 10/18/13 for the Period Ending 10/16/13

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

#### Powered By EDGAR Online

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	Name and Address of Reporting Person						and T	icke	r or T	adiı	ng Symb		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
10X Fund, L.I	P.			- 1	ALI FAI		HT	ER	APE	J <b>T</b> I	ICS IN	C Direct	or		_X 10% (	Owner		
(Last)	(First)	(Midd	le)	3. I	Date	of Earli	est Tra	ansa	ction (	MM/I	DD/YYYY	Office below)	Officer (give title below) Other (specify below)					
1099 FOREST	Γ LAKE	TERR	ACE				10/1	16/2	2013									
	(Street)				4. If Amendment, Date Original Filed 6. Individual or Joint/Group Filing (Check MM/DD/YYYY) 6. Individual or Joint/Group Filing (Check Applicable Line)										eck			
NICEVILLE,	FL 325	78		ŀ														
(City)	(State)	(Zip)										X Form file	ed by One Re iled by More	eporting Pers than One Re	on coorting Pers	ion		
		Table I	- Non-D	eriva	tive	Securit	ies Ac	quir	ed, D	ispo	sed of, o	or Beneficiall			1			
1. Title of Security (Instr. 3)				2. Tran: Date	]	2A. Deemed Execution Date, if	3. Trans Code (Instr. 8	3)	4. Secur Acquire Dispose (Instr. 3	d (A) d of (	от Fo D) (I	Amount of Securiollowing Reported nstr. 3 and 4)	ities Benefic Transaction	ially Owned (s)	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
				***	ľ	any	Code	v	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)		
Common Stock				10/16/2	013		M		300000	A	\$3.00	925	7422 (1)		D			
Tab	le II - Dei	rivative S	ecuritie	s Ben	efici	ially Ov	vned (	e.g.	, puts	, cal	lls, warr	ants, options	, convert	ible secur	ities)			
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. De Se Ac or (E (Ir	Number of certivative ecurities equired (A Disposed 9) estr. 3, 4 a	f 6. Date	ate Ex Expira	Expir	e te	7. Title ar Securities Derivative (Instr. 3 a	d Amount of Underlying Security	8. Price of Derivative Security (Instr. 5)	9. Number	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
Class A-2 Warrants (right to buy)	\$3.00	10/16/2013		Code M	V (A	300000	-	/2009	2/12/	2014	Common Stock	Shares 300000	\$0	0	D			

#### **Explanation of Responses:**

(1) 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Reporting Owners

Reporting Owner Name / Address		Rel			
L	Director	10%	Owner	Officer	Other
10X Fund, L.P. 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578			X		
10X Capital Management, LLC 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578			X		

Signatures

/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	10/17/2013
** Signature of Reporting Person	Date
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	10/17/2013
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT R

## EXHIBIT R

## GALECTIN THERAPEUTICS INC Reported by 10X CAPITAL MANAGEMENT, LLC

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 11/05/13 for the Period Ending 11/01/13

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

#### Fowered By EDGAROnline

## FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
10X Fund, L.I	2.			$\mathbf{G}$	ΑI	ECTI	1 TE	HERA	APE	UT)	ICS IN	VC					
,				[ (	[ GALT ]								Directo	or		X 10% (	Owner
(Last)	(First)	(Mid	dle)	3.	3. Date of Earliest Transaction (MM/DD/YYYY)								Officer (give title below) Other (specify below)				specify
1099 FOREST	Γ LAKE	TERF	RACE				1	1/1/20	013								
	(Street)					Amendme	ent, D	Date Or	rigina	l File	ed		6. Individt Applicable Li		nt/Group I	Filing (Che	ck
NICEVILLE,	FL 325	78															
(City)	(State)	(Zip)											Form file X Form fi	ed by One Ro iled by More	eporting Perse than One Re	on porting Pers	on
		Table I	- Non-D	eriv:	ativ	e Securi	ties A	Acauir	ed. I	)ispo	sed of.	or B	eneficially	v Owned			
1.Title of Security (Instr. 3)	of Security :				ns.	2A. Deemed Execution Date, if	3. Tr Code	Trans. 4. Sode Acquistr. 8) Disp		Securities equired (A) or sposed of (D) str. 3, 4 and 5		5. Amount of Securities Benefici Following Reported Transaction (Instr. 3 and 4)		ially Owned	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
						any	Со	ode V	Amou	(A) or (D)			or Indirect (I) (Instr. 4)				(Instr. 4)
Common Stock				11/1/	2013		M	a	150000 A		\$3.00		9407422 (1)			D	
Common Stock				11/1/	2013		M	1	50000	A	\$3.00		9457422 (1)			D	
Tab	le II - Dei	rivative	Securitie	es Be	nef	cially O	wned	l ( e.g.	. nut	s. cal	lls. war	rant	s. ontions	convert	ible secur	rities)	
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A. Deemed	4. Trans Code (Instr. 8)	5. Number of Derivative Securities		f 6. ar or (D)	ded ( e.g. , puts, calls, warran 6. Date Exercisable and Expiration Date 7. Title and A Securities Un Derivative S (Instr. 3 and					nount of erlying urity		9. Number	10. Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code			1	ate xercisab		iration	Title		ount or nber of res		Transaction (s) (Instr. 4)	4)	
Class A-2 Warrants (right to buy)	\$3.00	11/1/2013		М		150000	5/	/13/2009	5/13	3/2019	Commo Stock	n	150000	<b>\$0</b> (2)	0	D	
Class A-2 Warrants (right to buy)	\$3.00	11/1/2013		M		50000	6/	/30/2009	6/3	0/2019	Commo Stock	n	50000	<b>\$0</b> (3)	33333	D	

#### **Explanation of Responses:**

- (1) 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- (2) On May 13, 2009, 10X Fund, L.P. purchased (a) 450,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 150,000 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 150,000 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 600,000 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$900,000.
- (3) On June 30, 2009, 10X Fund, L.P. purchased (a) 250,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 833,333 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 83,333 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 333,333 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$500,000.

APP000549

Reporting Owners

Reporting Owner Name / Address	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
10X Fund, L.P. 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578		X							
10X Capital Management, LLC 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578		X							

#### Signatures

/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	11/5/2013				
** Signature of Reporting Person					
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	11/5/2013				
** Signature of Reporting Person	Date				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT S

## EXHIBIT S

APP000551

## GALECTIN THERAPEUTICS INC Reported by 10X CAPITAL MANAGEMENT, LLC

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 01/29/14 for the Period Ending 01/27/14

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

### FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	ress of Re	porting I	Person *	2.	Iss	uer Name	and	Tick	er or	Trac	lir	ng Symt	ool 5. Relation (Check all			Person(s)	to Issue
10X Fund, L.I	P.					LECTIN	TH	IER	AP]	EUT	ΓI	CS IN	I.	^^	,	_X 10% (	Owner
(Last)	(First)	(Mid	dle)			te of Earli	est T	`ransa	ctio	n (MI	⁄I/I	DD/YYYY	Officer below)	(give title	below)	Other (	(specify
1099 FOREST	T LAKE	TERF	RACE		1/27/2014												
	(Street)			4.	If A	Amendme	nt, D	ate O	rigir	nal F	ile	ed	6. Individu		nt/Group ]	Filing (Che	ck
NICEVILLE,	FL 325	78		(10)	11/1/12	10/1111)							Applicable Li	ne)			
(City)	(State)	(Zip)	)												eporting Pers e than One Re		on
		Table I	. Non-I	)ariv	ativ	a Sacurit	ios A	eani	rođ	Dier		and of a	or Beneficially	Owned			
1.Title of Security		1 ADIC I	11011-1	2. Tra		2A.	3. Tra		1	curitie			Amount of Securi			6.	7. Nature
(Instr. 3)	•			Date		Deemed Execution Date, if	Code (Instr.		Disp	oired ( osed o r. 3, 4	f(	or   Fo D)   (I	ollowing Reported nstr. 3 and 4)			Ownership Form:	of Indirect Beneficial Ownership
						any	Cod	ie V	Amo	(	A) or O)	Price					(Instr. 4)
Common Stock				1/27/	2014		М		3333	<del>-  `</del>	<u></u>	\$3.00	23095	19 (1) (2)		(4) D	
Common Stock			****	1/27/2	2014		М		5000	00 2	4	\$3.00	23595	19 (1) (2)		D	
Common Stock				1/27/	2014		М		5416	56 4	A	\$3.00	24136	85 (1) (2)		D	
Common Stock				1/27/	2014		М		5166	56	<b>A</b>	\$3.00	24653	51 (1) (2)		D	
Common Stock				1/27/	2014		М		5416	57	A	\$3.00	25195	18 (1) (2)		D	,
Common Stock				1/27/	2014		М		5416	57	A	\$3.00	25736	85 (1)(2)		D	
Common Stock				1/27/	2017		М		5583	34	A	\$3.00	<b>2629519</b> <sup>(1)</sup> <sup>(2)</sup>			D	
Common Stock				1/27/	2014		M	-	5166	57	A	\$3.00	26811	D			
Common Stock				1/27/	/27/2014				9500	00 4	A	\$3.00 2776186 (1) (2)				D	
Tab	le II - Dei	rivative	Securiti	es Be	nefi	icially Ow	vned	( e.g.	. DU	ıts. c	al	ls, warr	ants, options.	convert	ible secur	rities)	
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans.	3A.	4. Trans	de Securities		or D)	Date E d Expir	xercis	sable		7. Title ar	nd Amount of Underlying Security		9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	Beneficial
				Code	V (.	A) (D)	Da Ex	ite ercisal	ole Da			Title	Amount or Number of Shares		Transaction (s) (Instr. 4)		
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М		33333	6/3	30/2009	9 6/	30/20	19	Common Stock	33333	<b>\$0</b> (3)	0· ··	D	
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М		50000	8/1	12/2009	9 8/	12/20	19	Common Stock	50000	<b>\$0</b> (4)	0	D	
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		M		54166	9/3	30/2009	9 9/	30/20	19	Common Stock	54166	<b>\$0</b> (5)	0	D	
Class A-2 Warrant		1/27/2014							11	1/3/20:	19	Common			APP0	00553	

Tab	le II - Der	ivative	Securitio	es Be	ne	fici	ally Own	ed ( <i>e.g.</i> ,	puts, cal	lls, warr	ants, options	s, conver	tible secur	ities)			
1. Title of Derivate Security (Instr. 3)	1	3. Trans.	3A. Deemed Execution Date, if any	4. Trans	١.	5. N Der Sec Acc Dis	Jumber of ivative urities quired (A) or posed of (D) str. 3, 4 and	6. Date Exercisable and Expiration Date		7. Title an	d Amount of Underlying Security		9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction (s) (Instr. 4)				
(right to buy)	\$3.00			M			51666	11/3/2009		Stock	51666	\$0 <sup>(6)</sup>	0	D			
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М			54167	12/8/2009	12/8/2019	Common Stock	54167	<b>\$0</b> (7)	0	D			
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М			54167	1/29/2010	1/29/2020	Common Stock	54167	<b>\$0</b> (8)	0	D			
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М			55834	3/8/2010	3/8/2020	Common Stock	55834	<b>\$0</b> (9)	0	D			
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М			51667	4/30/2010	4/30/2020	Common Stock	51667	<b>\$0</b> (10)	0	D			
Class A-2 Warrant (right to buy)	\$3.00	1/27/2014		М			95000	5/10/2010	5/10/2020	Common Stock	95000	<b>\$0</b> (11)	0	D			

#### **Explanation of Responses:**

- (1) Amount reflects the Issuer's March 23, 2012 one-for-six reverse stock split. This filing amends all previous filings since the reverse stock split to reflect post-split beneficial holdings.
- (2) 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- (3) On June 30, 2009, 10X Fund, L.P. purchased (a) 250,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 83,333 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 83,333 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 333,333 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$500,000.
- (4) On August 12, 2009, 10X Fund, L.P. purchased (a) 150,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 50,000 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 50,000 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 200,000 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$300,000.
- (5) On September 30, 2009, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,166 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 54,166 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 216,666 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$325,000.
- (6) On November 3, 2009, 10X Fund, L.P. purchased (a) 155,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 51,666 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 51,666 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 206,667 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$310,000.
- (7) On December 8, 2009, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,167 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 54,167 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 216,667 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$325,000.
- (8) On January 29, 2010, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,167 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 54,167 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 216,667 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$325,000.
- (9) On March 8, 2010, 10X Fund, L.P. purchased (a) 167,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 55,834 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 55,834 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 223,333 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$335,000.
- (10) On April 30, 2010, 10X Fund, L.P. purchased (a) 155,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 51,667 shares of Common Stock for \$3.00 per share, (c) one Class A-2 Warrant to purchase 51,667 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 206,667 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$310,000.
- (11) On May 10, 2010, 10X Fund, L.P. purchased (a) 285,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase

95,000 shares of Common Stock for \$5.00 per share, (c) one Class A-2 Warrant to purchase 95,000 shares of Common Stock for \$3.00 per share, and (d) one Class B Warrant to purchase 380,000 shares of Common Stock for \$3.00 per share, for aggregate consideration of \$570,000.

Reporting Owners

Reporting Owner Name / Address	Relationships							
L	Director	10% Owner	Officer	Other				
10X Fund, L.P. 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578		X						
10X Capital Management, LLC 1099 FOREST LAKE TERRACE NICEVILLE, FL 32578		X						

#### Signatures

/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	1/29/2014
** Signature of Reporting Person	Date
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	1/29/2014
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## EXHIBIT T

## EXHIBIT T

APP000556

## GALECTIN THERAPEUTICS INC

## Reported by PRELACK STEVEN

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 02/04/14 for the Period Ending 01/31/14

Address 4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

Telephone 678-620-3186

CIK 0001133416

Symbol GALT

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31

#### Powered by EDGAROnline

### FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	1. Name and Address of Reporting Person *							and Ti	ick	er or T	rad	ing Syr	nbo	ol 5. Relation	ishin of I	Renorting	Person(s)	to Issuer
	2000 01 100	porumb	CIBON											(Check all	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
Prelack Steve	n							HTT I	ER	RAPE	UT	ICS I	N					
						L								X_Direc			10%	
(Last)	(First)	(Mid	ldle)	3.	Da	te o	t Earli	est Tra	ns	action	(MM	/DD/YY	YY)	Officer below)	r (give title l	pelow) _	Other	(specify
C/O GALEC	O GALECTIN THERAPEUTIC						1/31/2014											
INC., 4960 PI																		
INDUSTRIA		, STE	240															
	(Street)						endme YYY)	nt, Dat	e C	Origina	l Fil	ed		6. Individi Applicable Li		nt/Group I	Filing (Che	eck
NORCROSS,														X Form fi	led by One	Reporting Per	reon	
(City)	(State)	(Zip)	)											Form file	d by More t	han One Rep	orting Perso	a
		Table l	[ - Non-l	Deriv	ativ	e S	ecurit	ies Acc	qui	ired, I	isp	sed of	, or	Beneficially	y Owned			
1.Title of Security (Instr. 3)				2. Tra Date	ns.	2A.		3. Trans. Code		4. Secu Acquire			5. A	Amount of Secur llowing Reported	ities Benefic	cially Owned		7. Nature
				Date		Exe	ecution	(Instr. 8)		Dispose	ed of	(D)		str. 3 and 4)	Transaction	1(S)	Form:	of Indirect Beneficial
						any	te, if		Τ-	(Instr. 3	(A)	(0.5)	-				Direct (D) or Indirect	Ownership (Instr. 4)
								Code	\ <sub>V</sub>	Amoun	or	Price			1			
Common Stock				1/31/2	2014			М				3	1603		D			
Common Stock				1/31/2	31/2014			М		83334	A	\$1.20		86937			D	
Common Stock				1/31/2	2014			М		9260	A	\$6.48		96197			D	
Common Stock				1/31/2				M		8475	A	\$7.08		10	)4672		D	
Common Stock				1/31/2	2014			М	_	6269	A	\$3.59		11	10941		D	
Common Stock				1/31/2	2014			F		(9)	D	\$13.71		9	3219		D	
Tab	le II - De	rivative	Securiti	es Be	nefi	icial	lly On	vned (	e. 9	put	s. ca	lls. wa	rra	nts, options,	convert	ible secur	ities)	
Title of Derivate     Security	2. Conversion	3. Trans.	3A. Deemed	4. Trans.	5		mber of	6. Da	te E	exercisal ration D	le	7. Title	and	Amount of Inderlying		9. Number	10.	11. Nature of Indirect
(Instr. 3)	or Exercise Price of		Execution Date, if	Code (Instr.		Secur	ities ired (A)		1				ive S	Security		derivative	Form of	Beneficial
	Derivative Security	-	any	8)			sed of (I					(msu.	aud	1 4)	(msn. 5)	Beneficially		(Instr. 4)
	Security					Instr.	. 3, 4 and	i								Owned Following Reported	Direct (D) or Indirect (I) (Instr.	
						Ť		Date		Exp	ratio	Title		Amount or		Transaction (s) (Instr. 4)	4)	
				Code	V (	A)	(D)		isal	ble Date	:	Title		Number of Shares		(s) (mstr. 4)		
Stock Option (right to buy)	\$.72 <sup>(1)</sup>	1/31/2014		M			667 (1)	2/8/2	2009	2/8/	2014	Comm Stock		667	\$0	0	D	
Stock Option (right to buy)	\$1.20 (3)	1/31/2014		M		8	3334 (1	1)	(2)	2/25	/2014	Comm Stock		83334	\$0	0	D	
Stock Option (right to buy)	\$6.48 (4)	1/31/2014		M	9260 (4		9260 (4)	) (	(5)	3/24	/2016	Comm Stock		9260	\$0	0	D	
Stock Option (right to buy)	\$7.08 (6)	1/31/2014		M	8475 (6		8475 (6)	) (	(7)		6/28/2021 Common Stock			8475	\$0	0	D	
Stock Option (right to buy)	\$3.59	1/31/2014		M			6269		(8)	3/28	/2023	Comm Stock		6269	\$0	10445	D	
																APP00	IIIコウス	

#### **Explanation of Responses:**

- (1) This option was previously reported as covering 4,000 shares at an exercise price of \$0.12 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (2) Stock Option grant, vested as follows: (i) 50% on February 25, 2010; (ii) 25% on May 25, 2010; (iii) 12.5% on August 25, 2010; (iv) 6.25% on November 25, 2010; and (v) 6.25% on February 25, 2011.
- (3) This option was previously reported as covering 500,000 shares at an exercise price of \$0.2 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (4) This option was previously reported as covering 55,556 shares at an exercise price of \$1.08 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (5) The option vests in eight equal installments beginning May 12, 2011.
- (6) This option was previously reported as covering 50,848 shares at an exercise price of \$1.18 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (7) The option vests as to one-eighth of the shares on June 28, 2011 and thereafter quarterly in seven equal installments beginning August 12, 2011.
- (8) The option vests quarterly in eight equal installments beginning on May 12, 2013.
- (9) Represents shares forfeited in satisfaction of exercise price of vested options.

Reporting Owners

Reporting Owner Name / Address		Relationships								
Leoporting Owner Ivaine / Address	Director	10% Owner	Officer	Other						
Prelack Steven C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD, STE 240										
NORCROSS, GA 30071										

#### Signatures

/s/ Steven Prelack	2/3/2014
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.